Intrommune Therapeutics is a clinical stage biotechnology company that is developing convenient, safe and effective options for individuals suffering with food allergies. Intrommune’s therapies are delivered through a platform that integrates simply into a person’s daily routine to enable them and their loved ones to live their lives without fear. The Company’s Oral Mucosal Immunotherapy (OMIT) platform is based on the well-accepted principles of immunotherapy. OMIT utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patient’s immune system, while cleaning their teeth. The initial product in development is INT301 for the treatment of peanut allergy. The lack of treatments makes food allergies an area of tremendous unmet need. The FDA has only approved one product for any food allergy, a peanut allergy immunotherapy that requires you to ingest peanut protein. As desperate as patients are for solutions, due to significant adverse events and difficulty in administration, only 1 in 10 eligible patients are willing to ingest peanut protein. Nonetheless, the company was recently acquired for $2.6 billion. With minimal options, patients and caregivers must resort to attempting to avoid allergy-triggering foods in the often-futile hope of preventing severe allergic reactions. In short, patients, parents, providers and payors are all seeking a safe, efficacious, and easy to administer product such as INT301. Intrommune Therapeutics’ Phase 1b study in individuals with peanut allergy is on-going and is on a development timeline with significant near-term value inflection events expected over the next 12 months
